Achlys is a leading cardiac ion channel company offering better solutions for measuring drug-associated cardiotoxicity.
Our expert team from the Universities of Alberta and Calgary offer novel computational and biological assay systems to tell you if your drug candidates inhibit the hERG ion channel or other components within human cardiomyocytes.
One of the most common off-target effects for pharmaceutical drugs is via the cardiac hERG potassium channel. Blocking this channel can cause cardiotoxicity as can other off-target reactions within the human cardiomyocyte itself. Achlys provides a novel human cardiomyocyte cell-line expressing hERG to allow functional assays for different kinds of drug-associated cardiotoxicity. In addition, Achlys offers three different but complementary services you can use to improve your drug cardiotoxicity testing.